Erste Asset Management’s Pacific Biosciences PACB Stock Holding History

Erste Asset Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-63,500	Closed	-$833K	–	572
2023 Q2	$833K	Sell	63,500 -35,000	-36%	-$425K	0.01%	377
2023 Q1	$961K	Hold	98,500	–	–	0.02%	368
2022 Q4	$817K	Hold	98,500	–	–	0.02%	382
2022 Q3	$552K	Hold	98,500	–	–	0.01%	410
2022 Q2	$450K	Buy	98,500 +50,000	+103%	+$304K	0.01%	442
2022 Q1	$468K	Buy	+48,500	New	+$558K	0.01%	442
2021 Q4	–	Sell	-26,200	Closed	-$651K	–	555
2021 Q3	$651K	Hold	26,200	–	–	0.01%	376
2021 Q2	$944K	Hold	26,200	–	–	0.02%	349
2021 Q1	$785K	Sell	26,200 -25,800	-50%	-$903K	0.02%	348
2020 Q4	$1.32M	Buy	+52,000	New	+$884K	0.04%	311

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Erste Asset Management's PACB Position: Q3 2023 in Review

Erste Asset Management sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 63,500 shares — an estimated $833K sold.

Erste Asset Management first reported a position in PACB in Q4 2020 and held it in 10 quarters. The position peaked at $1.32M in Q4 2020. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

Erste Asset Management reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
Erste Asset Management sold 63,500 Pacific Biosciences shares in Q3 2023, an estimated $833K.
Erste Asset Management first reported a position in Pacific Biosciences in Q4 2020 and held it in 10 quarters.
Erste Asset Management's Pacific Biosciences position peaked at $1.32M in Q4 2020.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Erste Asset Management's 13F filing for Q3 2023, filed 26 Nov 2024.